Tradeoff between bleeding and stent thrombosis in different dual antiplatelet therapy regimes: Importance of case fatality rates and effective treatment durations - 29/10/14
, Matthias E. Pfisterer, MD a, i, Rikke Sørensen, MD b, Stefanie von Felten, PhD a, Hannes Alber, MD c, Piero O. Bonetti, MD d, Franz Eberli, MD e, Paul Erne, MD f, Giovanni Pedrazzini, MD g, Hans Rickli, MD h, Søren Galatius, MD b, Christoph A. Kaiser, MD afor the
BASKET and BASKET-PROVE investigators
Résumé |
Background |
The tradeoff between stent thrombosis (ST) and major bleeding (MB) of 12- versus 6-month dual antiplatelet therapy (DAPT) after coronary stent implantation has not been clearly defined.
Methods |
Definite/probable ST and MB (TIMI major and Bleeding Academic Research Consortium (BARC) ≥3) were compared in 2 subsequent trials with similar inclusion criteria but different DAPT duration, that is, BASKET (6 months; n = 557) and BASKET-PROVE (12 months; n = 2,314), between months 0 to 6 (DAPT in both trials), 7 to 12 (DAPT in BASKET-PROVE only), and 13 to 24 (aspirin in both trials) using propensity score-adjusted, time-stratified Cox proportional hazard models.
Results |
Overall, event rates were low with fewer ST but similar MB in prolonged DAPT. Analysis of the 3 periods showed a uniform pattern for ST (interaction DAPT/period; P = .145) but an inconsistent pattern for MB (interaction DAPT/period; P < .001 for TIMI major and P = .046 for BARC ≥3), with more MB occurring during months 7 to 12 with prolonged DAPT. Considering observed case fatality rates of 31% with ST and 11% with MB, the extrapolated prevention of 27 ST deaths and the excess of 5 MB deaths resulted in an expected benefit of 22 survivors/10,000 patients treated over 2 years with prolonged DAPT.
Conclusion |
Despite overall low event rates, prolonged DAPT was associated with more MB during months 7 to 12 according to the interaction DAPT/period. Given the higher observed case fatality rates of ST versus MB, 12- versus 6-month DAPT was associated with an extrapolated reduction in mortality. Effective treatment periods and case fatality rates seem important in the analysis of different DAPT durations, specifically with regard to ongoing trials.
Le texte complet de cet article est disponible en PDF.Plan
Vol 168 - N° 5
P. 698 - novembre 2014 Retour au numéro
Article précédent
- Rationale and design of a randomized controlled trial evaluating community health worker–based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD)
- Deepak Y. Kamath, Denis Xavier, Rajeev Gupta, P.J. Devereaux, Alben Sigamani, Tanvir Hussain, Sowmya Umesh, Freeda Xavier, Preeti Girish, Nisha George, Tinku Thomas, N. Chidambaram, Rajnish Joshi, Prem Pais, Salim Yusuf
- Transesophageal echocardiography in patients with cryptogenic ischemic stroke: A systematic review
- Emer R. McGrath, Jeremy S. Paikin, Bahareh Motlagh, Omid Salehian, Moira K. Kapral, Martin J. O'Donnell
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?